Press release
Global Transmucosal Drugs Market Size to grow at a CAGR of 6.85% to reach USD 28,191.42 million by 2032, Evaluates DelveInsight
DelveInsight's "Transmucosal Drugs Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transmucosal Drugs companies actively working in the market.
To know more about why North America is leading the market growth in the Transmucosal Drugs market, get a snapshot of the report Transmucosal Drugs Market Trends
https://www.delveinsight.com/sample-request/transmucosal-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Transmucosal Drugs Overview
Transmucosal drugs are medications administered across a mucous membrane-such as the oral, nasal, buccal (inside the cheek), sublingual (under the tongue), or rectal mucosa-to enter the bloodstream directly. This route allows for rapid absorption, bypassing the digestive system and first-pass metabolism in the liver, which can improve onset of action and bioavailability. Common examples include sublingual nitroglycerin for angina, buprenorphine films for pain or opioid dependence, and nasal sprays for migraine or hormonal therapy. Transmucosal delivery is especially useful for drugs needing fast effects or improved systemic absorption.
DelveInsight Analysis: The transmucosal drugs market size was valued at USD 16,652.02 million in 2024, is expected to grow at a CAGR of 6.85% from 2025 to 2032, reaching USD 28,191.42 million by 2032.
Transmucosal Drugs Market Insights
Geographically, North America is projected to hold the largest share of the transmucosal drugs market in 2024. This dominance is driven by the growing prevalence of chronic conditions such as hypertension and neurological disorders, along with intensified R&D efforts by major industry players. These factors collectively contribute to the region's strong market growth.
To read more about the latest highlights related to Transmucosal Drugs, get a snapshot of the key highlights entailed in the Transmucosal Drugs Insights
https://www.delveinsight.com/report-store/transmucosal-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Recent Developments in the Transmucosal Drugs Market Report
• In March 2024, BIAL, launched KYNMOBI (apomorphine hydrochloride) in Germany. KYNMOBI is the sublingual film for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease.
• In March 2024, Tonix Pharmaceuticals announced its collaboration with Almac Pharma Services for the launch and commercialization of TonmyaTM (cyclobenzaprine HCl sublingual tablets) in the U.S. Tonmya is a centrally acting opioid analgesic for the treatment of fibromyalgia.
• In December 2022, Aquestive Therapeutics, announced the completion of phase-2 clinical trial for AQST-109. It is an epinephrine sublingual film designed to treat severe allergic reactions such as anaphylaxis.
• Thus, owing to such developments in the market, rapid growth will be observed in the Transmucosal Drugs market during the forecast period
Key Players in the Transmucosal Drugs Market
Some of the key market players operating in the Transmucosal Drugs market include- Teva Pharmaceutical Industries Ltd, Indivior PLC, GSK plc, Emergent BioSolutions Inc., Bayer AG, AbbVie Inc., Organon group of companies, Pfizer Inc., Prestige Consumer Healthcare, Inc., Merck & Co., Inc., Aquestive Therapeutics, Inc., Ferring, Novartis AG, Adalvo Limited, Sumitomo Pharma Co., Ltd., ZIM LABORATORIES LIMITED, BioXcel Therapeutics, Inc., BIAL, Almac Group, Boehringer Ingelheim International GmbH, and others.
Which MedTech key players in the Transmucosal Drugs market are set to emerge as the trendsetter explore @ Key Transmucosal Drugs Companies
https://www.delveinsight.com/sample-request/transmucosal-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Analysis on the Transmucosal Drugs Market Landscape
Leading companies are actively developing new transmucosal tablet formulations to enhance their market presence. These innovations help expand their pharmaceutical portfolios and demonstrate their commitment to meeting diverse patient needs. For example, in February 2024, Adalvo Limited introduced Desmopressin sublingual tablets in France for managing diabetes insipidus, primary nocturnal enuresis, and nocturia. Such product launches are expected to support market expansion.
Overall, the benefits and wide-ranging applications of transmucosal tablets will continue to bolster segment growth, thereby driving the overall transmucosal drugs market throughout the forecast period.
Scope of the Transmucosal Drugs Market Report
• Coverage: Global
• Study Period: 2022-2032
• Transmucosal Drugs Market Segmentation By Product: Nasal Spray, Tablet, Film, and Others
• Transmucosal Drugs Market Segmentation By Route Of Administration: Oral, Nasal, Sublingual, Buccal, and Others
• Transmucosal Drugs Market Segmentation By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
• Transmucosal Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Transmucosal Drugs Companies: Teva Pharmaceutical Industries Ltd, Indivior PLC, GSK plc, Emergent BioSolutions Inc., Bayer AG, AbbVie Inc., Organon group of companies, Pfizer Inc., Prestige Consumer Healthcare, Inc., Merck & Co., Inc., Aquestive Therapeutics, Inc., Ferring, Novartis AG, Adalvo Limited, Sumitomo Pharma Co., Ltd., ZIM LABORATORIES LIMITED, BioXcel Therapeutics, Inc., BIAL, Almac Group, Boehringer Ingelheim International GmbH, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Interested in knowing how the Transmucosal Drugs market will grow by 2032? Click to get a snapshot of the Transmucosal Drugs Market Analysis
https://www.delveinsight.com/sample-request/transmucosal-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Transmucosal Drugs Market Size to grow at a CAGR of 6.85% to reach USD 28,191.42 million by 2032, Evaluates DelveInsight here
News-ID: 4273924 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Transmucosal
Transmucosal Drug Delivery Devices: A Leading Driver Behind Growth In Chronic Di …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Transmucosal Drug Delivery Devices Industry Market Size Be by 2025?
In the past few years, the market size of transmucosal drug delivery devices has significantly increased. The market is predicted to grow from the value of $50.24 billion in 2024 to $54.63 billion in 2025, with…
Oral Transmucosal Drugs Market Future Demand Highlighted by Persistence Market R …
The global oral transmucosal drugs market has been experiencing significant growth, and this upward trajectory is projected to continue. By 2025, the market is expected to be valued at $38.43 billion, reaching $62.55 billion by 2032, growing at a CAGR of 7.2%. The increasing prevalence of chronic diseases and the growing need for innovative and effective drug delivery systems are major factors driving this expansion. Oral transmucosal drug delivery methods…
Oral Transmucosal Drugs: Core Growth Enabler in the Parkinson's Disease Driving …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Oral Transmucosal Drugs Industry Market Size Be by 2025?
Significant growth has been observed in recent years in the market for oral transmucosal drugs. The market, valued at $39.7 billion in 2024, is predicted to expand to $43.21 billion in 2025, with a compound annual growth…
Leading Element Driving Change in the Oral Transmucosal Drugs Market in 2025: Pa …
How Are the key drivers contributing to the expansion of the oral transmucosal drugs market?
The rising incidence of Parkinson's disease is expected to boost the oral transmucosal drug market. Parkinson's disease, a progressive neurological disorder, is becoming more prevalent due to an aging population, environmental factors, and better diagnostic techniques. Oral transmucosal drugs offer fast absorption and relief, enhancing treatment adherence and reducing motor complications. According to the Parkinson's Foundation,…
Growth In Chronic Diseases Propels Transmucosal Drug Delivery Devices Market: Ma …
How Will the Transmucosal Drug Delivery Devices Market Grow, and What Is the Projected Market Size?_x000D_
The market for transmucosal drug delivery devices has notably expanded in the past few years. The market worth, which currently stands at $50.24 billion in 2024, is predicted to increase to $55.04 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. This significant growth during the historical period can be ascribed…
Transmucosal Drug Delivery Systems Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Transmucosal Drug Delivery Systems Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Transmucosal Drug Delivery Systems market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million…
